

# International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,<sup>1</sup> notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 62 Prop. INN not later than 31 May 1990.

*The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.*

## Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INN. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will be neither revised nor included in the Cumulative Lists of INN.

## Proposed International Nonproprietary Names (Prop. INN): List 62<sup>2</sup>

Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*: twentieth report of the WHO Expert Committee). ISBN 92 4 120581 4 (price: Sw. fr. 6.-); an account of this publication will be found in Annex 2 of the present List. All names from Lists 1-58 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative List No. 7*, 1988. World Health Organization, Geneva (ISBN 92 4 0560149) (price: Sw. fr. 65.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to March 1988. The printout also indicates in which of the 58 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.


These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

<sup>1</sup> Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld. Hlth Org.*, 1955, 60, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld. Hlth Org.*, 1969, 173, 10).

<sup>2</sup> Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7*, 1988.


acidum risedronicum  
risedronic acid

[1-hydroxy-2-(3-pyridyl)ethylidene]diphosphonic acid  
C<sub>7</sub>H<sub>11</sub>NO<sub>7</sub>P<sub>2</sub> 105462-24-6 *calcium regulator*




actaritum  
actarit

(*p*-acetamidophenyl)acetic acid  
C<sub>10</sub>H<sub>11</sub>NO<sub>3</sub> 18699-02-0 *immunomodulator*




aloracetamum  
aloracetam

*N*-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide  
C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> 119610-26-3 *nootropic agent*




alprafenonum  
alprafenone

(±)-3-[3-[2-hydroxy-3-(*tert*-pentylamino)propoxy]-4-methoxyphenyl]-  
4'-methylpropiophenone  
C<sub>25</sub>H<sub>35</sub>NO<sub>4</sub> 124316-02-5 *antidysrhythmic*




ataprostum  
ataprost  
6552

(+)-(2*E*,3*aS*,4*R*,5*R*,6*aS*)-4-[(1*E*,3*S*)-3-cyclopentyl-3-hydroxypropenyl]-  
3,3*a*,4,5,6,6*a*-hexahydro-5-hydroxy-*A*<sup>2(1*H*,<sup>δ</sup></sup>-pentalenevaleric acid  
C<sub>21</sub>H<sub>32</sub>O<sub>4</sub> 83997-19-7 *platelet aggregation inhibitor*




batoprazinum  
batoprazine

8-(1-piperaziny)coumarin  
C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> 105685-11-8 *psychotropic*




brifentanilum  
brifentanil

*cis-N*-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-  
fluoro-2-methoxyacetanilide  
C<sub>20</sub>H<sub>29</sub>FN<sub>6</sub>O<sub>3</sub> 101345-71-5 *narcotic analgesic*




butenafinum  
butenafine

*N*-(*p-tert*-butylbenzyl)-*N*-methyl-1-naphthalenemethylamine  
C<sub>23</sub>H<sub>27</sub>N 101828-21-1 *antifungal*




candoxatrilatum  
candoxatrilat

(*αS*)-1-[(*cis*-4-carboxycyclohexyl)carbamoyl]-*α*-[(2-methoxyethoxy)methyl]-  
cyclopentanepropionic acid  
C<sub>20</sub>H<sub>33</sub>NO<sub>7</sub> 123122-54-3 *antihypertensive*




candoxatrilum  
candoxatril

(*αS*)-1-[(*cis*-4-carboxycyclohexyl)carbamoyl]-*α*-[(2-methoxyethoxy)methyl]cyclopentanepropionic acid, *α*-5-indanyl ester  
C<sub>29</sub>H<sub>41</sub>NO<sub>7</sub> 123122-55-4 *antihypertensive*




cericlaminum  
cericlamine

(±)-3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methyl-1-propanol  
C<sub>12</sub>H<sub>17</sub>Cl<sub>2</sub>NO 112922-55-1 *antidepressant*




ciclesonidum  
ciclesonide

11 $\beta$ ,16 $\alpha$ ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate  
C<sub>32</sub>H<sub>44</sub>O<sub>7</sub> *glucocorticosteroid*




daniquidonum  
daniquidone

8-aminoisoindolo[1,2-*b*]quinazolin-12(10*H*)-one  
C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O 67199-66-0 *antineoplastic*




dapropterinum  
dapropterin

(-)-(6*R*)-2-amino-6-[(1*R*,2*S*)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3*H*)-  
pteridinone  
C<sub>9</sub>H<sub>15</sub>N<sub>5</sub>O<sub>3</sub> 62989-33-7 *antihyperphenylalaninaemic*




desfluranum  
desflurane

(±)-difluoromethyl 1,2,2,2-tetrafluoroethyl ether  
C<sub>3</sub>H<sub>2</sub>F<sub>6</sub>O 57041-67-5 *general anaesthetic*




devazepidum  
devazepide

(*S*)-*N*-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl)indole-  
2-carboxamide  
C<sub>25</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> 103420-77-5 *cholecystokinin receptor antagonist*




dexrazoxanum  
dexrazoxane

(+)-(*S*)-4,4'-propylenedi-2,6-piperazinedione  
C<sub>11</sub>H<sub>16</sub>N<sub>4</sub>O<sub>4</sub> 24584-09-6 *antineoplastic*



ditekirenum  
ditekiren

*tert*-butyl (2*S*)-2-[[[*αS*]-*a*-[[[1*S*]-1-[[[1*S*,2*S*,4*S*)-2-hydroxy-1-isobutyl-5-methyl-  
4-[[[1*S*,2*S*)-2-methyl-1-[(2-pyridylmethyl)carbamoyl]butyl]carbamoyl]-  
hexyl]carbamoyl]-2-imidazol-4-ylethyl]methylcarbamoyl]phenethyl]-  
carbamoyl]-1-pyrrolidinecarboxylate  
C<sub>50</sub>H<sub>75</sub>N<sub>9</sub>O<sub>8</sub> 103336-05-6 *renin inhibitor*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use

dosmalfatum  
dosmalfate

$[\mu_6\text{-}[[\text{diosmin octasulfato}](8\text{-})]]\text{tetracontahydroxyhexadecaaluminum}$   
 $\text{C}_{28}\text{H}_{64}\text{Al}_6\text{O}_{79}\text{S}_8$  122312-55-4 *antacid*



duteplasum  
duteplase


245-L-methionineplasminogen activator (human tissue-type 2-chain form protein moiety)  
 $\text{C}_{2736}\text{H}_{4174}\text{N}_{914}\text{O}_{824}\text{S}_{46}$  120608-46-0 *thrombolytic*

ecogramostimum  
ecogramostim

N-L-methionylcolony-stimulating factor 2 (human U937 cell protein moiety reduced)  
123120-99-0 *immunostimulant*

elsamitricinum  
elsamitricin

10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- $\alpha$ -D-galactopyranosyl)-6-deoxy-3-C-methyl- $\beta$ -D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[*h*][1]-benzopyrano[5,4,3-*cde*][1]benzopyran-5,12-dione  
 $\text{C}_{33}\text{H}_{35}\text{NO}_{13}$  97068-30-9 *antineoplastic*



epoetinum alfa  
epoetin alfa


1-165-erythropoietin (human clone  $\lambda$ HEPOFL13 protein moiety)  
 $\text{C}_{809}\text{H}_{1301}\text{N}_{229}\text{O}_{240}\text{S}_5$  113427-24-0 *antianaemic*

epoetinum beta  
epoetin beta

1-165-erythropoietin (human clone  $\lambda$ HEPOFL13 protein moiety), glycoform  $\beta$   
 $\text{C}_{809}\text{H}_{1301}\text{N}_{229}\text{O}_{240}\text{S}_5$  122312-54-3 *antianaemic*


eptastigminum  
eptastigmine

*N*-demethyl-*N*-heptylphysostigmine or (3*aS*,8*aR*)-1,2,3,3*a*,8,8*a*-hexahydro-1,3*a*,8-trimethylpyrrolo[2,3-*b*]indol-5-yl heptylcarbamate  
C<sub>21</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> 101246-68-8 *acetylcholinesterase inhibitor*




fedotozinum  
fedotozine

(+)-(*R*)- $\alpha$ -ethyl-*N,N*-dimethyl- $\alpha$ -[[[(3,4,5-trimethoxybenzyl)oxy]methyl]benzyl]amine  
C<sub>22</sub>H<sub>31</sub>NO<sub>4</sub> 123618-00-8 *gastrointestinal agent*




finasteridum  
finasteride

*N-tert*-butyl-3-oxo-4-aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -carboxamide  
C<sub>23</sub>H<sub>36</sub>N<sub>2</sub>O<sub>2</sub> 98319-26-7 *antineoplastic*



fluvastatinum  
fluvastatin

( $\pm$ )-(*3R*\*,*5S*\*,*6E*)-7-[3-(*p*-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoic acid  
C<sub>24</sub>H<sub>26</sub>FO<sub>4</sub> 93957-54-1 *antihyperlipidaemic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


fosinoprilatum  
fosinoprilat

(4S)-4-cyclohexyl-1-[[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline  
 $C_{23}H_{34}NO_5P$  95399-71-6  
angiotensin converting enzyme  
inhibitor




fosphenytoinum  
fosphenytoin

3-(hydroxymethyl)-5,5-diphenylhydantoin, dihydrogen phosphate (ester)  
 $C_{16}H_{15}N_2O_6P$  93390-81-9  
antiepileptic




fosquidonum  
fosquidone

benzyl 5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isoindolo-  
[2,1-b]isoquinolin-9-yl hydrogen phosphate  
 $C_{28}H_{22}NO_6P$  114517-02-1  
antineoplastic




gemcitabinum  
gemcitabine

2'-deoxy-2', 2'-difluorocytidine  
 $C_9H_{11}F_2N_3O_4$  95058-81-4  
antineoplastic




girisopamum  
girisopam

1-(*m*-chlorophenyl)-7,8-dimethoxy-4-methyl-5*H*-2,3-benzodiazepine  
C<sub>18</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub> 82230-53-3 *anxiolytic*




glipalamidum  
glipalamide

(±)-5-methyl-N-(*p*-tolylsulfonyl)-2-pyrazoline-1-carboxamide  
C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S 37598-94-0 *antidiabetic*




ipazilidum  
ipazilide

N-[3-(diethylamino)propyl]-4,5-diphenylpyrazole-1-acetamide  
C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O 115436-73-2 *antidysrhythmic*




isbufyllinum  
isbufylline

7-isobutyltheophylline  
C<sub>11</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> 90162-60-0 *antiasthmatic*




itrocinnonidum  
itrocinnonide

6*α*,9-difluoro-11*β*,16*α*,17-trihydroxy-3-oxoandrosta-1,4-diene-17*β*-carboxylic acid, ester with ethyl (*S*)-1-hydroxyethyl carbonate, cyclic (*R*)-16,17-acetal with butyraldehyde  
C<sub>29</sub>H<sub>38</sub>F<sub>2</sub>O<sub>9</sub> 106033-96-9 *glucocorticosteroid*




levemopamilum  
levemopamil

(-)-(S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile  
C<sub>23</sub>H<sub>30</sub>N<sub>2</sub> 101238-51-1 *calcium antagonist*




levetiracetamum  
levetiracetam

(S)- $\alpha$ -ethyl-2-oxo-1-pyrrolidineacetamide  
C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> 102767-28-2 *nootropic agent*




lidanserinum  
lidanserin

(±)-4-[3-[3-[4-(*p*-fluorobenzoyl)piperidino]propoxy]-4-methoxyphenyl]-2-pyrrolidinone  
C<sub>26</sub>H<sub>31</sub>FN<sub>2</sub>O<sub>4</sub> 73725-85-6 *serotonin antagonist*




lifibrolum  
lifibrol

(±)-*p*-[4-(*p*-*tert*-butylphenyl)-2-hydroxybutoxy]benzoic acid  
C<sub>21</sub>H<sub>26</sub>O<sub>4</sub> 96609-16-4 *antihyperlipidaemic*




melquinastum  
melquinast

ethyl 6-ethyl-5,6-dihydro-9-methyl-5-oxo-s-triazolo[1,5-c]quinazoline-2-carboxylate  
C<sub>15</sub>H<sub>16</sub>N<sub>4</sub>O<sub>3</sub> 87611-28-7 *antiallergic*




meribendanum  
meribendan

4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2H)-pyridazinone  
 $C_{15}H_{14}N_6O$  119322-27-9 *positive inotropic agent*




nardeterolum  
nardeterol

(±)-α-[[[3-(1-benzimidazolyl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzyl alcohol  
 $C_{20}H_{24}FN_3O_2$  73865-18-6 *β<sub>2</sub>-adrenoreceptor agonist*




neltenexinum  
neltexine

4',6'-dibromo-α-[(trans-4-hydroxycyclohexyl)amino]-2-thiophene-carboxy-*o*-toluidide  
 $C_{18}H_{20}Br_2N_2O_2S$  99453-84-6 *mucoytic*




nepinalonum  
nepinalone

(±)-3,4-dihydro-1-methyl-1-(2-piperidinoethyl)-2(1H)-naphthalenone  
 $C_{18}H_{25}NO$  22443-11-4 *antitussive*




nitecaponum  
nitecapone

3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione  
 $C_{12}H_{11}NO_6$  116313-94-1 *antiparkinson*




oxilofrinum  
oxilofrine

*erythro-p*-hydroxy- $\alpha$ -[1-(methylamino)ethyl]benzyl alcohol  
C<sub>10</sub>H<sub>15</sub>NO<sub>2</sub> 365-26-4 *sympathomimetic*




pancopridum  
pancopride

(±)-4-amino-5-chloro- $\alpha$ -cyclopropyl-N-3-quinuclidinyl-*o*-anisamide  
C<sub>18</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub> 121650-80-4 *antiemetic, anxiolytic*




pantoprazolum  
pantoprazole

5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-  
benzimidazole  
C<sub>16</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>S 102625-70-7 *antiulcer*




pibaxizinum  
pibaxizine

[2-[2-[4-(diphenylmethylene)piperidino]ethoxy]ethoxy]acetic acid  
C<sub>24</sub>H<sub>29</sub>NO<sub>4</sub> 82227-39-2 *antispasmodic, antihistaminic*




pilsicainidum  
pilsicainide

tetrahydro-1*H*-pyrrolizine-7a(5*H*)-aceto-2',6'-xylidide  
C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O 88069-67-4 *antidysrhythmic*




quinagolidum  
quinagolide

(±)-N,N-diethyl-N-[(3*R*,4*aR*,10*aS*)-1,2,3,4,4*a*,5,10,10*a*-octahydro-6-hydroxy-1-propylbenzo[*g*]quinolin-3-yl]sulfamide  
C<sub>20</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub>S 87056-78-8 *D*<sub>2</sub>-dopamine receptor agonist




risotilidum  
risotilide

4'-[isopropyl[2-(isopropylamino)ethyl]sulfamoyl]methanesulfonanilide  
C<sub>15</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> 120688-08-6 *antidysrhythmic*




rociclovirum  
rociclovir

2-amino-9-[[2-isopropoxy-1-(isopropoxymethyl)ethoxy]methyl]purine  
C<sub>15</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> 108436-80-2 *antiviral*




sampirtinum  
sampirtine

2,6-diamino-3-(*p*-fluorobenzyl)pyridine  
C<sub>12</sub>H<sub>12</sub>FN<sub>3</sub> 115911-28-9 *anti-inflammatory*



sarafloxacinum  
sarafloxacin

6-fluoro-1-(*p*-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid  
C<sub>20</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> 98105-99-8 *antibacterial (vet.)*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


saviprazolum  
saviprazole

2-[[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)-2-pyridyl]methyl]sulfinyl]-1H-  
thieno[3,4-d]imidazole  
C<sub>15</sub>H<sub>10</sub>F<sub>7</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub> 121617-11-6 *antiulcer*




secalciferolum  
secalciferol

(5Z,7E,24R)-9,10-secosterolesta-5,7,10(19)-triene-3β,24,25-triol  
C<sub>27</sub>H<sub>44</sub>O<sub>3</sub> 55721-11-4 *calcium regulator*




sezolamidum  
sezolamide

(+)-(S)-5,6-dihydro-4-(isobutylamino)-4H-thieno[2,3-b]thiopyran-  
2-sulfonamide 7,7-dioxide  
C<sub>11</sub>H<sub>15</sub>N<sub>2</sub>O<sub>4</sub>S<sub>3</sub> 123308-22-5 *carbonic anhydrase inhibitor*



sobuzoxanum  
sobuzoxane

4,4'-ethylenebis[1-(hydroxymethyl)-2,6-piperazinedione] bis(isobutyl  
carbonate) (ester)  
C<sub>22</sub>H<sub>34</sub>N<sub>4</sub>O<sub>10</sub> 98631-95-9 *antineoplastic*



Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use

somalaporum  
somalapor


*N*-L-alanyl-growth hormone (pig clone pPGH-1 reduced)  
C<sub>977</sub>H<sub>1527</sub>N<sub>265</sub>O<sub>287</sub>S<sub>7</sub> 106282-98-8 *growth hormone*

somenoporum  
somenopor

*N*-L-alanyl-32-de-L-glutamic acid-33-de-L-arginine-34-de-L-alanine-35-de-L-tyrosine-36-de-L-isoleucine-37-de-L-proline-38-de-L-glutamic acid-growth hormone (pig clone pPGH-1 reduced)  
C<sub>938</sub>H<sub>1469</sub>N<sub>255</sub>O<sub>275</sub>S<sub>7</sub> 119693-74-2 *growth hormone*


timirdinum  
timirdine

3-(2-amino-4-chlorophenyl)-2-iminothiazolidine  
C<sub>9</sub>H<sub>10</sub>ClN<sub>3</sub>S 100417-09-2 *antidepressant*




tiracizinum  
tiracizine

ethyl 5-(*N,N*-dimethylglycyl)-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-3-carbamate  
C<sub>21</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> 83275-56-3 *antidysrhythmic*



trelnarizinum  
trelnarizine

(*E*)-1-[bis(*p*-fluorophenyl)methyl]-4-(3,4-dimethoxycinnamyl)piperazine  
C<sub>28</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> 123205-52-7 *vasodilator*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


tropisetronum  
tropisetron

1 $\alpha$ H,5 $\alpha$ H-tropan-3 $\alpha$ -yl indole-3-carboxylate  
C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> 89565-68-4 serotonin antagonist




vapreotidum  
vapreotide

D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-tryptophanamide cyclic (2→7)-disulfide  
C<sub>57</sub>H<sub>70</sub>N<sub>12</sub>O<sub>9</sub>S<sub>2</sub> 103222-11-3 antineoplastic



zatebradinum  
zatebradine

3-[3-[(3,4-dimethoxyphenethyl)methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one  
C<sub>26</sub>H<sub>36</sub>N<sub>2</sub>O<sub>5</sub> 85175-67-3 bradycardic agent



## Names for Radicals and Groups


Some substances for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved

may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals

and groups have been devised or selected, and they are suggested for use with the proposed international non-proprietary names.


bezomilum  
bezomil

(benzyloxy)methyl  
 $C_8H_7O_2$



erbuminum  
erbumine

*tert*-butylamine  
 $C_4H_{11}N$



hyclas  
hyclate


monohydrochloride hemiethanoiate hemihydrate  
 $\frac{1}{2}(C_{22}H_{10}Cl_2O_2)$

$\frac{1}{2}(2HCl \cdot C_2H_5OH \cdot H_2O)$



**Proposed International Nonproprietary Names (Prop. INN): List 61**

- |        |  |  |
|--------|--|--|
| p. 88  | bakeprofenum<br>bakeprofen   | <i>replace the CAS registry number by the following:</i><br>117819-25-7  |
| p. 89  | carboxirolum<br>carboxirole  | <i>replace the action and use statement by the following:</i><br>D <sub>2</sub> -dopamine receptor agonist                       |
| p. 95  | gevotrolinum<br>evotroline   | <i>replace the chemical name by the following:</i><br>8-fluoro-2,3,4,5-tetrahydro-2-[3-(3-pyridyl)propyl]-1H-pyrido[4,3-b]indole |
| p. 98  | natrii borocaptate ( <sup>10</sup> B)<br>sodium borocaptate ( <sup>10</sup> B) | <i>replace the molecular formula by the following:</i><br><sup>10</sup> B <sub>12</sub> H <sub>12</sub> Na <sub>2</sub> S        |
| p. 105 | cefprozilum<br>cefprozil   | <i>replace the graphic formula by the following:</i>   |



**Procedure and Guiding Principles**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.

1

2

3

4

5

6

7

8

9